|
BioScreening - organic compounds for screening
Compound LibrariesSpermatech Selects Evotec as Partner for High-Throughput Screening and Lead Discovery - Hamburg, Germany | Oxford, UK | Oslo, Norway - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that Spermatech A/S has chosen them as a partner to identify small molecule therapeutics for their pharmaceutical discovery project.
Through the study of the physiology of sperm motility, more specifically of “rapid swimmers” that cause fertilisation, Spermatech have identified [...]
Bucks County’s Institute for Hepatitis and Virus Research and BioLeap Collaborate on New Discoveries - New Hope, PA — (SBWIRE) — 10/10/2007 — Bucks County’s Institute for Hepatitis and Virus Research (IHVR) and BioLeap have entered into a collaboration to develop new therapeutic compounds for the treatment of Hepatitis C. Up to 50% of patients treated with current standard therapies do not respond adequately and often suffer serious side effects [...]
Cisbio international’s upcoming third annual “HTRF® In Drug Discovery” Symposium will be held September 26-28 in Sonoma, California - Over the course of three days, experts in drug screening from around the globe will assemble to discuss the latest applications of Cisbio’s proprietary HTRF® technology in the drug screening, target discovery and mechanistic fields. A number of scientific sessions will specifically examine GPCR and kinase screening, cell-based biomarker detection [...]
Evotec and Research Support International Limited Announce the Formation of Evotec-RSIL Ltd, a Joint Venture for the Design, Synthesis, Management and Commercialisation of Compound Libraries - HAMBURG, Germany and OXFORD, England, July 11, 2007 /PRNewswire-FirstCall/ — Evotec AG and Research Support International Limited (RSIL), a subsidiary of DIL Ltd, announced today the formation of a joint venture in India, Evotec-RSIL Ltd, to design, synthesise and manage compound libraries as a service. The joint venture will combine Evotec’s expertise in library design, [...]
WUSTL creates center to study women’s infectious diseases - Washington University School of Medicine in St. Louis is launching a new effort to study infectious diseases that preferentially affect women. The center for Women’s Infectious Disease Research (cWIDR) will focus on issues such as:
• microorganisms that cause urinary tract infections (UTIs) and other conditions that make urination and intercourse painful or difficult
• infections that [...]
Amylin invests $10M in BioSeek - BioSeek, based in Burlingame, will work with San Diego-based Amylin (NASDAQ: AMLN) on treatments for inflammatory diseases. The work will put Amylin’s proprietary drug compounds through BioSeek’s biological screening systems to seek useful drugs. BioSeek can choose two peptide compounds after screening and develop them if it wishes, paying milestones and royalties to Amylin if [...]
Proprietary Formulation Technologies Advancing in Preclinical Drug Development - New Report by Applied Data Research Analyzes the Impact on Drug Development Timelines
(Nashua, NH) – As the availability of new tools for automating the drug discovery process identifies potential drug candidates at an accelerating rate, the formulation limitations of a majority of these new NCEs is creating a bottleneck in preclinical development. Drug developers are [...]
Evotec Discontinues EVT 301 Development Programme - HAMBURG, Germany and OXFORD, England, September 13 /PRNewswire-FirstCall/ — Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today reported that during the one month safety and tolerability study with EVT 301 in young and elderly volunteers, several cases of asymptomatic elevated liver function tests in the elderly group have been observed. All cases reversed spontaneously. [...]
Virtual screening services collaboration between Quantum Pharma and TimTec - Quantum Pharma, a drug discovery and computational chemistry software and contract services provider, Moscow, Russia, and TimTec, a provider of synthetic organic and natural compounds for bioscreening, Delaware, US, singed up a collaboration agreement. Quantum computational chemistry software with unique capabilities is available now through TimTec. In the future companies will co-develop products for drug-discovery [...]
Key Organics Ltd and Reaction Biology Corporation Announce New Library Screening Format - CORNWALL, England and MALVERN, Pa., June 1 /PRNewswire/ — Key Organics Ltd (”Key”) and Reaction Biology Corporation (”RBC”) today announced that they have teamed up to provide a new library screening format to customers. Beginning this summer, the entire Key Bionet library of 37,500 diverse drug-like compounds will be offered for “rental” screening on RBC’s [...]
Elsevier MDL and Key Organics partner to improve chemical sourcing - San Ramon, CA, May 8, 2006 - Elsevier MDL, producer of the MDL® Available Chemicals Directory and MDL® Screening Compounds Directory databases, and Key Organics Ltd., a leading supplier of screening compounds and chemical building blocks, have partnered in an effort to provide improved access to timely, accurate information for chemical sourcing and procurement for [...]
Otava presents a new human Fibroblast Growth Factor Receptor 1 Tyrosine Kinase (FGFR1K) focused library with 1901 compounds - This library has been created as a part of a project aimed at design of a large set of receptor-based sharp-focused libraries. In the framework of this project, Life Chemicals provides its Collection of 300 000 compounds and subsequent chemical optimization. Otava provides its drug-like Green Collection (50 000 compounds) and also is responsible for [...]
HUGIN NEWS/SENEXIS AND BIOFOCUS COLLABORATE TO SELECT DEVELOPMENT CANDIDATES FOR SENEXIS’ ALZHEIMER’S DISEASE TARGETS - Galapagos service division BioFocus will use its medicinal chemistry capabilities to accelerate the optimisation of Senexis’ novel inhibitors of amyloid-induced toxicity and neuroinflammation
Cambridge, UK, and Mechelen, Belgium, 2 December 2005 - Senexis Limited, a private drug development company, and Galapagos NV (Euronext & LSE: GLPG), a genomics based drug discovery company, announced today that they [...]
TimTec announces 10-year anniversary - October 17, 2005
TIMTEC INC, Delaware—TimTec Inc. is expressing customer and business partner appreciation as the company marks 10-years anniversary on the market of early drug-discovery.
Ten years in business, TimTec has matured into an internationally recognized expert in comprising diversity and targeted library collections tailored to fit drug discovery trends. Presently the company features its premier [...]
Angiotech Announces Drug Discovery And Development Agreement with CombinatoRx - Exclusive Collaboration With Initial Focus on Peripheral Vascular,
Coronary, and Orthopedic Indications
VANCOUVER, Oct. 3 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,
TSX: ANP) today announced a license and research collaboration agreement with
CombinatoRx, Incorporated focused on the selection and development of novel
combination pharmaceutical compounds for Angiotech’s [...]
Sigma-Aldrich Introduces the MyriaScreen Diversity Collection for Drug Discovery - TimTec and Sigma-Aldrich (NASDAQ:SIAL) are pleased to announce the availability of the MyriaScreen Diversity Collection of drug-like screening compounds produced in collaboration, as a result of careful evaluation, filtering, and refinement of selections from each of our screening compound collections. The MyriaScreen Diversity Collection is comprised of 10,000 high-purity screening compounds handpicked to maximize chemical [...]
Sponsored Links
|
|
